Regulatory compliance – Page 35

Validation gaps identified during system upgrades – inspection evidence expectations

Playbook for Identifying and Addressing Validation Gaps During System Upgrades Validation gaps during system upgrades can pose significant risks to compliance within pharmaceutical manufacturing. These gaps not only jeopardize production…

Raw data traceability failure during routine studies – alignment with OECD principles

Addressing Raw Data Traceability Failures During Routine Studies with OECD Principles The integrity of raw data is paramount during routine studies in pharmaceutical manufacturing and quality control. A failure in…

Unreported serial number events during system integration – preventing repeat serialization deviations

Addressing Unreported Serial Number Events During System Integration to Prevent Serialization Deviations The pharmaceutical industry often faces challenges during system integration, particularly with unreported serial number events. Such lapses can…

Change impact not assessed during change control – inspection evidence expectations

Assessing Change Impact in Change Control: A Comprehensive Playbook for Compliance In pharmaceutical manufacturing, the rigorous process of change control is fundamental to maintaining compliance and ensuring product quality. However,…

Traceability breaks in supply chain during regulatory inspection – preventing repeat serialization deviations

Mitigating Supply Chain Traceability Disruptions During Regulatory Inspections In the highly regulated pharmaceutical industry, maintaining robust traceability in the supply chain is paramount. However, traceability breaks can occur during the…

Validation gaps identified during site expansion – regulatory deficiency risk

Addressing Validation Gaps Found During Facility Expansion to Mitigate Regulatory Deficiencies With the rapid growth of the pharmaceutical industry, site expansions often create numerous challenges, particularly concerning validation protocols. Regulatory…

Traceability breaks in supply chain during distribution – recall readiness impact

Addressing Traceability Breaks in Distribution and Their Impact on Recall Readiness In the pharmaceutical industry, maintaining effective traceability throughout the supply chain is crucial for ensuring product integrity and compliance…

Validation gaps identified during change control – regulatory deficiency risk

Addressing Validation Gaps During Change Control to Mitigate Regulatory Risks Validation gaps during change control can lead to substantial regulatory deficiencies, particularly under the scrutiny of compliance inspections by the…

Raw data traceability failure during study reconstruction – inspection deficiency risk analysis

Analyzing Raw Data Traceability Failures During Study Reconstruction in Pharma In the pharmaceutical landscape, raw data traceability is crucial for maintaining compliance with regulatory requirements and ensuring data integrity. A…

Aggregation failures during distribution – inspection questioning scenarios

Addressing Aggregation Failures During Distribution: A Comprehensive Playbook In the pharmaceutical industry, aggregation failures during distribution can lead to significant compliance risks and operational inefficiencies. Such failures not only jeopardize…

Inadequate worst-case selection during change control – risk-based validation alignment

Addressing Inadequate Worst-case Selection During Change Control for Risk-based Validation In the ever-evolving landscape of pharmaceutical manufacturing, inadequate worst-case selection during change control presents significant regulatory risks. Insufficient analysis not…

System access controls weak during inspection walkthrough – 21 CFR Part 11 compliance gaps

Addressing Weak System Access Controls During Inspections to Ensure 21 CFR Part 11 Compliance Pharmaceutical manufacturing facilities are under constant scrutiny to maintain compliance with regulations governing electronic records and…